论文部分内容阅读
晚期不可切除肝癌免疫联合治疗方案的临床试验近期相继获得成功(Imbrave150、Keynote524)，显著提高了晚期不可切除肝癌的客观反应率与中位生存期，为后续肝癌外科治疗的介入提供了巨大的潜力与现实性。最近，免疫联合治疗的热点问题有：联合治疗方案该如何选择、围手术期应如何使用以及肿瘤免疫微环境、免疫治疗有效的生物标志物等方面。本文拟就上述相关问题做一综述。“,”Recently, the clinical trials of combined immunotherapy for advanced hepatocellular were completed successfully (Imbrave150, Keynote524), which have significantly increased the objective response rate and prolonged median overall survival time. The success of combined immunotherapy provides great potential and reality for subsequent surgical intervention of advanced hepatocellular carcinoma. Nowadays, the hot topics of combined immunotherapy include the choices of combined immunotherapy, the perioperative period determination, tumor immune microenvironment, and effective biomarkers of immunotherapy selection, and so on. This paper intends to summarize the above-related issues.